Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyoko Yamaguchi

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Nature Communications|October 19, 2024
Spatial dynamics of CD39<sup>+</sup>CD8<sup>+</sup> exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancerKenro Tanoue, Hirofumi Ohmura, Koki Uehara, et al.
Cancer Science|August 25, 2018
Epithelial-mesenchymal transition is activated in CD44-positive malignant ascites tumor cells of gastrointestinal cancerMichitaka Nakano, Mamoru Ito, Risa Tanaka, et al.
Blood|January 9, 2024
Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signatureSalma B Abdelbaky, Brian Giacopelli, Kari G Rabe, et al.
Hematological Oncology|December 24, 2024
Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic LeukemiaElena Bibikova, Sara Parsa, Muskan Floren, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 6, 2022
Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma modelKyoko Yamaguchi, Tomoyasu Yoshihiro, Hiroshi Ariyama, et al.
Molecular Cancer Therapeutics|March 18, 2014
Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathwayPeiwen Yu, A Douglas Laird, Xiangnan Du, et al.
Molecular Cancer Therapeutics|February 1, 2015
The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor ModelsPaul Foster, Kyoko Yamaguchi, Pin P Hsu, et al.
Journal of Medicinal Chemistry|February 12, 2013
Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR)Craig S Takeuchi, Byung Gyu Kim, Charles M Blazey, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Nature Communications|October 19, 2024
Spatial dynamics of CD39<sup>+</sup>CD8<sup>+</sup> exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancerKenro Tanoue, Hirofumi Ohmura, Koki Uehara, et al.
Cancer Science|August 25, 2018
Epithelial-mesenchymal transition is activated in CD44-positive malignant ascites tumor cells of gastrointestinal cancerMichitaka Nakano, Mamoru Ito, Risa Tanaka, et al.
Blood|January 9, 2024
Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signatureSalma B Abdelbaky, Brian Giacopelli, Kari G Rabe, et al.
Hematological Oncology|December 24, 2024
Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic LeukemiaElena Bibikova, Sara Parsa, Muskan Floren, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 6, 2022
Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma modelKyoko Yamaguchi, Tomoyasu Yoshihiro, Hiroshi Ariyama, et al.
Molecular Cancer Therapeutics|March 18, 2014
Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathwayPeiwen Yu, A Douglas Laird, Xiangnan Du, et al.
Molecular Cancer Therapeutics|February 1, 2015
The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor ModelsPaul Foster, Kyoko Yamaguchi, Pin P Hsu, et al.
Journal of Medicinal Chemistry|February 12, 2013
Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR)Craig S Takeuchi, Byung Gyu Kim, Charles M Blazey, et al.
Pageof 5